WADA prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-29. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
80 K-H Phosphoprotein (Protein Kinase C Substrate) (AGE-R2): The 80 K-H phosphoprotein, also known as protein kinase C substrate (AGE-R2), is involved in the intracellular signaling response to AGE exposure. AGE-R2 plays a role in regulating pathways that help cells adapt to oxidative stress by modulating protein kinase C (PKC) activity. This regulation aids in maintaining cellular homeostasis and mitigating the harmful effects of AGEs on cellular structures, ultimately contributing to the cell's resilience against oxidative stress. Galectin-3 (AGE-R3): Galectin-3, a member of the lectin family, is a multifunctional receptor that binds to AGEs and helps clear them from the extracellular space. This receptor is known for its involvement in modulating apoptosis, cell proliferation, and immune responses. Upon binding AGEs, Galectin-3 activates downstream signaling pathways, including those involving mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-κB), which are crucial for inflammatory regulation. By mediating these pathways, Galectin-3 reduces the pro-inflammatory effects of AGE accumulation and helps maintain tissue integrity. Its role in regulating apoptosis and immune cell recruitment further contributes to limiting AGE-induced tissue damage, thus playing a protective role in chronic inflammatory and fibrotic conditions. LOX-1 (Lectin-like Oxidized Low-Density Lipoprotein Receptor-1): LOX-1 is primarily known for binding oxidized low-density lipoproteins (oxLDL) but also binds AGEs.
state of Oklahoma to settle allegations that it had been overprescribing opioids, marketing them as safe, and downplaying their addictive qualities. In July 2019, Teva paid $69 million to settle pay-for-delay claims. In January 2020, Teva Pharmaceuticals agreed to pay $54 million to settle allegations under the False Claims Act that it violated the Anti-Kickback Statute by funding improper speaking programs to boost prescriptions. In 2021, New York Attorney General Letitia James filed a lawsuit against Teva and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. In February 2022, Teva agreed to a $225 million settlement with the state of Texas to end claims that it fueled an opioid epidemic in the state by improperly marketing pain medicine. In August 2023, Teva admitted to price-fixing charges related to the generic cholesterol drug Pravastatin, and agreed to pay a $225 million fine, after a criminal investigation by the US Department of Justice. The US Department of Justice stated that the settlement was "the largest to date for a domestic antitrust cartel." Also in August 2023, Teva agreed to a legal settlement with US hospitals over its marketing of opioid products that ultimately raised costs for health providers and contributed to the opioid epidemic in the United States. The lawsuit consisted of roughly 500 hospitals and health providers, resulting in a payment from Teva of $126 million over 18 years.
== Human sexual orientation and behavior genetics == In the 1990s Hamer began studies on the genetics of human behavior, which led to the first molecular evidence for genes that influence human sexual orientation. His research group's first paper, published in Science in 1993, reported that the maternal but not paternal male relatives of gay men had increased rates of same-sex orientation, suggesting the possibility of sex-linked transmission in a portion of the population. A genetic linkage analysis of DNA samples from these families showed that gay brothers had an increased probability of sharing polymorphic markers on the subtelomeric region of the long arm of the X chromosome, Xq28, providing statistically significant evidence for linkage to the sexual orientation phenotype. This finding was replicated in two other studies in the United States whereas a study in Canada found contrary results; meta-analysis of all data available at that time suggested that Xq28 has a significant but not exclusive effect. Subsequently, a genomewide scan by Hamerʻs group revealed additional regions on autosomes that were moderately linked to male sexual orientation. Hamer's results were supported in 2014 in a large, multi-center genetic linkage study of male sexual orientation. This study's analysis of 409 pairs of gay brothers with over 300,000 single-nucleotide polymorphism markers confirmed the Xq28 linkage by two-point and multipoint LOD score mapping.
==== Regular ==== 22 SAS is under the operational command of the Director Special Forces (DSF), a major-general grade post. Previously ranked as a brigadier, the DSF was promoted from brigadier to major-general in recognition of the significant expansion of the United Kingdom Special Forces (UKSF).
Sources: en.wikipedia.org
==== MeSH E05.200.249 – culture techniques ==== MeSH E05.200.249.249 – cell culture techniques MeSH E05.200.249.374 – coculture techniques MeSH E05.200.249.437 – diffusion chambers, culture MeSH E05.200.249.468 – embryo culture techniques MeSH E05.200.249.484 – organ culture techniques MeSH E05.200.249.617 – tissue culture techniques MeSH E05.200.249.750 – tissue engineering
==== Men's lacrosse ==== The lacrosse club team was founded in the mid-1960s. In the 1960s, Arizona was a Division I varsity program, coached by Carl Runk, an Arizona graduate and football player. In 1998, Runk retired after twenty-eight years at Towson University in Maryland.
In January 2026, TCI Express acquired of 100% of the equity shares of TCI Global (Singapore) through its wholly owned subsidiary, TCI Express Pte. Ltd. The shares were acquired from TCI Holdings Asia Pacific, a step down wholly owned subsidiary of Transport Corporation of India. TCI Global (Singapore) had reported no turnover during the preceding three financial years.
== Sources == AH Brogan, Committed to Saving Lives: a History of the Commonwealth Serum Laboratories (Melbourne: Hyland House, 1990). Dando McCredie, The Fight Against Disease and CSL's Seventy Year Contribution (Richmond: Dando McCredie, c.1986). FG Morgan, 'The Commonwealth Serum Laboratories and their work', Collected Proceedings of the Society of Chemical Industry of Victoria, XXXV (1935), 1015–31. WJ Penfold, 'The Commonwealth Serum Laboratories', Medical Journal of Australia, 1 (14 April 1923), 396–400. Struan K Sutherland, A Venomous Life: the Autobiography of Professor Struan Sutherland (Melbourne: Hyland House, 1998).
Breed identity is established through breed-registration records, while birthplace and rearing history are checked through the traceability system. This Wagyu designation is narrower than the Japanese origin category "domestic beef" (国産牛, kokusan-gyū), which generally applies when the animal was raised in Japan for longer than in any other country. Domestic beef therefore includes qualifying Wagyu as well as beef from Western-derived dairy breeds such as Holstein and Jersey, and from crosses between dairy and beef cattle. Beef from these dairy breeds and dairy–Wagyu crosses may be sold as domestic beef but does not qualify as Wagyu. Wagyu herds were also established outside Japan from cattle and genetic material exported beginning in the 1970s, particularly in the United States and Australia. Registered cattle in both countries include fullblood animals descended entirely from Japanese foundation stock as well as animals crossbred with other breeds. Breed associations maintain separate registers for these categories and use documented pedigrees, Wagyu ancestry percentages, and DNA parentage testing to determine registration. These are cattle-registration systems, whereas the Japanese guideline applies to the labeling of beef and also includes domestic birth and rearing requirements.
Sources: en.wikipedia.org
=== Microanatomy === The thymus consists of two lobes, merged in the middle, surrounded by a capsule that extends with blood vessels into the interior. The lobes consist of an outer cortex rich with cells and an inner less dense medulla. The lobes are divided into smaller lobules 0.5-2 mm in diameter, between which extrude radiating insertions from the capsule along septa. The cortex is mainly made up of thymocytes and epithelial cells. The thymocytes, immature T cells, are supported by a network of the finely-branched epithelial reticular cells, which is continuous with a similar network in the medulla. This network forms an adventitia to the blood vessels, which enter the cortex via septa near the junction with the medulla. Other cells are also present in the thymus, including macrophages, dendritic cells, and a small amount of B cells, neutrophils and eosinophils. In the medulla, the network of epithelial cells is coarser than in the cortex, and the lymphoid cells are relatively fewer in number. Concentric, nest-like bodies called Hassall's corpuscles (also called thymic corpuscles) are formed by aggregations of the medullary epithelial cells. These are concentric, layered whorls of epithelial cells that increase in number throughout life. They are the remains of the epithelial tubes, which grow out from the third pharyngeal pouch of the embryo to form the thymus.
Inhaling heroin appears to rarely lead to toxic leukoencephalopathy. There are also documented cases of both severe acute asthma and exacerbation of underlying asthma caused by heroin inhalation, potentially resulting in death.
=== Isotopic variation === The discovery of isotopes of oxygen in 1929 required a more precise definition of the unit. Two distinct definitions came into use. Chemists choose to define the AMU as 1/16 of the average mass of an oxygen atom as found in nature; that is, the average of the masses of the known isotopes, weighted by their natural abundance. Physicists, on the other hand, defined it as 1/16 of the mass of an atom of the isotope oxygen-16 (16O).
After Reagan's military buildup, the Soviet Union did not respond by further building its military, because the enormous military expenses, along with inefficient planned manufacturing and collectivized agriculture, were already a heavy burden for the Soviet economy. At the same time, Saudi Arabia increased oil production, even as other non-OPEC nations were increasing production. These developments contributed to the 1980s oil glut, which affected the Soviet Union as oil was the main source of Soviet export revenues. Issues with command economics, oil price decreases and large military expenditures gradually brought the Soviet economy to stagnation.
January 10, 2010: Canada Canada continues its long and laborious recovery over its recession. However, people are starting to lose optimism due to the continued job losses. Only Manitoba has managed to create 2000 new jobs while the rest of the nation loses approximately 105,000. The previous month brought in 36,000 new part-time jobs at the expense of 71,000 full-time jobs.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.